Frailty was a significant predictor of severe outcomes and hospitalization characteristics in older adults hospitalized with RSV infection.

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

Shifts in RSV testing methodology, which were accelerated by changes related to the COVID-19 pandemic, mirror shifts seen in ...

Protection against RSV derived from preF IgG antibodies waned 6 months after infection in an analysis of patients with confirmed disease and household contacts.

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

Introduction Respiratory syncytial virus (RSV) is one of the leading causes of severe respiratory infections worldwide, particularly among newborns, infants, young children, the elderly, and ...

Respiratory Syncytial Virus (RSV) is a major cause of acute respiratory tract infections (ARTIs) and can trigger outbreaks in vulnerable settings such as nursing homes, pediatric wards, and neonatal ...

The rapid identification of respiratory virus outbreaks is needed to enable rational and effective public health interventions. We developed new quantitative approaches for simultaneous ...

We sought to investigate if cardiac pathology (inflammation, fibrosis, cardiomyocyte damage) and CNS pathology (encephalitis) develop together during simian immunodeficiency virus (SIV) infection and ...

About ENFLONSIA™ (clesrovimab-cfor) ENFLONSIA is Merck’s extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory syncytial virus (RSV) lower ...

Respiratory viruses are the leading cause of lower respiratory tract infection (LRTI) and hospitalisation in infants and young children. Respiratory syncytial virus (RSV) is the main infectious agent ...